

Public Offering

# 60 Months EUR 100 per cent. Capital Protected Certificates Linked to FTSE MIB Index

#### Term Sheet

All material herein is for discussion purposes only and is only a summary. Reference should be made to the Programme, which contains the only legally binding terms of the Certificates and other information related to the issue. Investors should read the section "Significant Risks" below as well as the section "Risk Factors" of the Programme. Investors are subject to the credit risk of the Issuer. Until the Issue Date, the terms of this Termsheet are indicative and may be adjusted anytime. The Issuer is not obliged to issue the Product.

PRODUCT DESCRIPTION			
Product Description	The Redemption at maturity will depend on the performance of th Cash Settlement in an amount equal to the Capital Protection Underlying, as described under "Redemption". The Redemption Ar	Level plus an amount li	nked to the
Market expectation of the Investor	The investor expects a moderate rise in the Underlying(s). The inve close higher than the Strike Level on the Final Fixing Date of the Pro to bear the risk of a decline in the price of the Underlying.		, .
EUSIPA / SSPA Code	1199 – Miscellaneous Capital Protection		

PRODUCT DETAILS		DATES	
ISIN	IT0006751868	Initial Fixing Date	31 August 2022
CFI Code	DSCYVI	Issue Date	09 September 2022
Issue Price	EUR 1,000.00	Final Fixing Date	31 August 2027
Issue Size	10,000 Certificates	Redemption Date	09 September 2027
Nominal Amount	EUR 1,000		
Settlement Currency	EUR		
Minimum Investment	1 Certificate		

UN	DERLYING					
i	Underlying	Index Sponsor	Reference Currency	Bloomberg Ticker	Initial Fixing Level (100%)*	Strike Level (100.00%)*
1	FTSE MIB Index	FTSE International Limited	EUR	FTSEMIB Index	21,559.32	21,559.32

\* as determined on or about the Initial Fixing Date (levels are expressed in percentage of the Initial Fixing Level).

# GENERAL INFORMATIONIssuerMarex Financial, 155 Bishopsgate, London, EC2M 3TQ, United Kingdom.Issuer RatingBBB (S&P Global).Supervision of the IssuerThe Issuer is authorised and regulated in the United Kingdom by the Financial Conduct Authority ("FCA").Lead Manager &<br/>Calculation AgentMarex Financial.



Principal Programme BNP Paribas Securities Services, Milan Branch, Piazza Lina Bo Bardi 3, 20124 Milan. Agent

REDEMPTION		
Formula	The investor is entitled to receive from the Issuer on the Redemption Date an amount per Certificate in the Settlement Currency as determined by the Calculation Agent as follows:	
	Min (Cap; [Nominal Amount x (Capital Protection Level + (Participation x Max (0%, Performance – 100.00%)))])	
Initial Fixing Level	Official closing price of the Underlying on the Initial Fixing Date as published by the Index Sponsor and as determined by the Calculation Agent.	
Final Fixing Level	Official closing price of the Underlying on the Final Fixing Date as published by the Index Sponsor as determined by the Calculation Agent by reference to the Bloomberg page related to the Underlying.	
Capital Protection Level	100.00%	
Сар	EUR 1,500.00	
Participation	100.00%	
Performance	The performance of the Underlying is calculated as the Final Fixing Level divided by the Initial Fixing Level.	

FURTHER INFORMATION		
Unique Identifier	ee0d1223-709c-48ad-85be-51a4390dd0ff	
Programme	Base Prospectus dated 30 September 2021 as supplemented from time to time, including the relevant Final Terms of the Product.	
Notices	All notices concerning the Securities, including adjustments and corrections to the terms and conditions will be published on www.marexfp.com and notified to Monte Titoli.	
Listing/Exchange	The Certificates may be listed on EuroTLX (a multilateral trading facility organised and managed by Borsa Italiana). No assurances are given that such listing will be obtained.	
Business Days for payment purposes	TARGET.	
Business Day Convention	Following.	
Secondary Market	Under normal market conditions the lead manager will endeavour to quote secondary prices with a 1.001% bid and offer spread. The securities may only be sold to a third party with the prior consent of the Lead Manager and only in the form of a private placement. Thus, investors must contact the Lead Manager before they resell the Securities.	
Quoting Type	Currency quotation. The securities are quoted dirty and any accrued interest is included in the secondary market price.	
Settlement Type	Cash Settlement.	
Selling Restrictions	The Products may not be offered or sold within the United States or to, or for the account or benefit of US persons (as defined in Regulation S). Detailed information on Selling Restrictions is published in the Programme which is available on <a href="https://www.marexfp.com">www.marexfp.com</a> .	
Clearing	Monte Titoli.	
Offer	Public Offering (see below under "Offering Information").	



Offer State(s)	Italy, Luxembourg.
Form	Registered.
Governing Law / Jurisdiction	English / England
Section 871(m)	The Issuer has determined that the Products will not be subject to withholding under Section 871(m) of the U.S. Internal Revenue Code.

Positive Target Market	Target Market Category	Positive TM	
	INVESTOR TYPE	Retail, Professional Client & Eligible Counterparty	
	KNOWLEDGE AND EXPERIENCE	Informed & Advanced	
	ABILITY TO BEAR LOSSES	No Capital Loss	
	RISK TOLERANCE	Medium	
	INVESTMENT OBJECTIVES	Income	
	DISTRIBUTION STRATEGY	Execution Only & Investment Advice	
	Time Horizon	Medium Term	
	May be terminated early?	NO	
Negative Target Market	Target Market Category	Negative TM	
	KNOWLEDGE AND EXPERIENCE	Basic	

The Target Market Category is based on "Target Market Section" of the European MiFID Template - Version 4.0 definitions https://www.bvi.de/en/services/samples-and-working-aids/european-mifid-template-emt/

Costs & Charges

Entry Costs: 5.59%

Exit Costs: Not Applicable

## TAXATION

Investors and prospective investors are advised to consult with their tax advisers with respect to the tax consequences of the purchase, ownership, disposition, lapse or exercise or redemption of a Product in light of their particular circumstances. The Issuer and the Lead Manager hereby expressly exclude any liability in respect of any possible tax implications.

#### Information with regards to FATCA (Foreign Account Tax Compliance Act)

Any payment under this Product may be subject to withholding tax (such as, inter alia, withholding related to FATCA or 871(m) of the US Tax Code). Any payments due under this Product are net of such tax. If an amount in respect of Section 871(m) of the U.S. Tax Code were to be deducted or withhold from interest, principal or other payments on the Products, none of the Issuer, any Paying Agent or any other person would be required to pay additional amounts as a result of the deduction or withholding of such tax, i.e. the investor would receive a significant lower amount than he would have received without such deduction or withholding.

## OFFERING INFORMATION

Information for Italian, Luxembourg investors: This document is not a prospectus in terms of Regulation (EU) 2017/1129, and may not be interpreted as such. Reference should be made to the published Base Prospectus including any supplements thereto and the final terms relating to the Products, which contain the only legally binding terms of the Products. The final terms relating to the Products will be published in Italy on the first day of the public offering. The Base Prospectus, any supplements thereto and the Final Terms will be available for investors from the first day of the public offering in electronic form on the website www.marexfp.com. These documents are also obtainable free of charge at 155 Bishopsgate, London, EC2M 3TQ (United Kingdom), via telephone (+44 (0)207-650-4404\*) or



via e-mail (sales@marexfp.com). The public offering of the Products in the Offer States is expected to commence on the date stated above as the Start of Public Offering.

You understand that no action has been taken by Marex Financial to permit a public offering of the Products in any jurisdiction other than the ones stated above.

You agree that: (i) you will not offer, sell or deliver any of the Products described in this material in any jurisdiction, except in compliance with all applicable laws, and (ii) you will take, at your own expense, whatever action is required to permit your purchase and resale of the Securities. Where you receive a selling commission from Marex Financial you confirm that such payment complies with all applicable law in the territory into which you distribute the product, including where applicable that; (i) you have disclosed the nature and amount of the payment to the extent you are required to do so; (ii) you have confirmed that the receipt of any payment by you from Marex Financial does not conflict with your duty to act in the best interests of those to whom you owe such duties; and (iii) you have determined that the payment is designed to enhance the quality of the service to any investor seeking to invest in the investments set out in this material.

# PRODUCT DOCUMENTATION

Notices to investors in connection with this Product shall be validly given in accordance with the terms and conditions of the Programme.

During the whole term of this Product, the Product Documentation can be ordered free of charge from the Calculation Agent/the Issuer at 155 Bishopsgate, London, EC2M 3TQ (United Kingdom), via telephone (+44 (0)207-650-4404\*) or via e-mail (sales@marexfp.com). Please note that all calls made to numbers marked with an asterisk (\*) are recorded. By calling such number, your consent to the recording is deemed given.

# SIGNIFICANT RISKS

## Risk Factors Relating to the Product

The risk of loss related to this Product at Redemption is limited to the difference between the purchase price per Certificate and the Nominal Amount multiplied by the predefined Capital Protection Level. However, this product offers capital protection at Redemption only and if an investor sells the product prior to the Redemption Date, the market price may be substantially less than the Nominal Amount multiplied by such Capital Protection Level.

## Additional Risk Factors

Prospective investors should ensure that they fully understand the nature of this Product and the extent of their exposure to risks and they should consider the suitability of this Product as an investment in the light of their own circumstances and financial condition. Products involve a high degree of risk, including the potential risk of expiring worthless. Potential investors should be prepared in certain circumstances to sustain a total loss of the capital invested to purchase this Product. Prospective investors shall consider the following important risk factors and see the section "Risk Factors" of the Programme for details on all other risk factors to be considered.

This is a structured product involving derivative components. Investors should make sure that their advisors have verified that this Product is suitable for the portfolio of the investor taking into account the investor's financial situation, investment experience and investment objectives.

The terms and conditions of the Product may be subject to adjustments during the lifetime of the Product as set out in the Programme. Investors whose usual currency is not the currency in which the Product is redeemed should be aware of their possible currency risk. The value of the Product may not correlate with the value of the Underlying.

#### Market Risks

The general market performance of securities is dependent, in particular, on the development of the capital markets which, for their part, are influenced by the general global economic situation as well as by the economic and political framework conditions in the respective countries (so-called market risk). Changes to market prices such as interest rates, commodity prices or corresponding volatilities may have a negative effect on the valuation of the Underlying(s) or the Product. There is also the risk of market disruptions (such as trading or stock market interruptions or discontinuation of trading) or other unforeseeable occurrences concerning the respective Underlyings and/ or their stock exchanges or markets taking place during the term or upon maturity of the Products. Such occurrences can have an effect on the time of redemption and/or on the value of the Products.



### No Dividend Payment

This Product does not confer any claim to receive rights and/ or payments of the Underlying, such as dividend payments, unless explicitly stated herein, and therefore, without prejudice to any coupon or dividend payments provided for in this Termsheet, does not yield any current income. This means that potential losses in value of the Product cannot be compensated by other income.

### Credit Risk of Issuer

Investors bear the credit risk of the Issuer of the Product. The value of the Products is dependent not only on the Underlyings, but also on the creditworthiness of the Issuer, which may change over the term of the Product.

The Products constitute unsubordinated and unsecured obligations of the Issuer and rank pari passu with each and all other current and future unsubordinated and unsecured obligations of the Issuer. The insolvency of the Issuer may lead to a partial or total loss of the invested capital.

#### Secondary Market

The Issuer and/or the Lead Manager or any third party appointed by the Issuer, as applicable, intends, under normal market conditions, to provide bid and offer prices for the Products on a regular basis (if specified in the section "General Information"). However, the Issuer and/ or the Lead Manager, as applicable, make no firm commitment to provide liquidity by means of bid and offer prices for the Products, and assume no legal obligation to quote any such prices or with respect to the level or determination of such prices. In special market situations, where the Issuer and/ or the Lead Manager is/ are unable to enter into hedging transactions, or where such transactions are very difficult to enter into, the spread between the bid and offer prices may be temporarily expanded, in order to limit the economic risks of the Issuer and/ or the Lead Manager. Investors must be prepared to hold the Securities until the Redemption Date.

#### Illiquidity Risk

One or, if applicable, more of the Underlyings might be or become illiquid over the life time of the Product.

Illiquidity of an Underlying might lead to larger bid/ offer spreads of the Product and/or to an extended time period for buying and/ or selling the Underlying respective to acquire, unwind or dispose of the hedging transaction(s) or asset(s) or to realise, recover or rem it the proceeds of such hedging transaction(s) or asset(s) which might implicate a postponed redemption or delivery and/ or a modified redemption amount, as reasonably determined by the Calculation Agent.

# ADDITIONAL INFORMATION / DISCLAIMERS

## Conflict of Interests

The Issuer and/or the Lead Manager and/or any third party appointed by them, as the case may be, may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market as well as be active on both sides of the market at the same time in any securities, currencies, financial instruments or other assets underlying the products to which this document relates. The Issuer's and/ or Lead Manager's and/ or the appointed third party's trading and/ or hedging activities related to this transaction may have an impact on the price of the Underlying and may affect the likelihood that any relevant threshold (e.g. a Barrier Level/Price), if any, is reached.

## Remunerations to Third Parties

Depending on the circumstances the Issuer and/ or Lead Manager may sell this Product to financial institutions or intermediaries at a discount to the Issue Price or reimburse a certain amount to such financial institutions or intermediaries (reference is made to section "General Information" herein). For open-end products such fees will be split linearly over ten years.

In addition, for certain services rendered by distribution partners and to increase quality and services relating to the Products, the Issuer and/or Lead Manager may from time to time pay trailer fees to such third parties.

Further information is available on request.

#### Payment of a Coupon

If the Product stipulates the payment of a coupon, the investor is only entitled to receive the respective coupon payment, if he has purchased/not sold the Product at the latest on the business day preceding the respective Coupon Payment Date for the then prevailing price.

#### No Offer

The Termsheet is primarily provided for information purposes and does not constitute a recommendation, an offer or a solicitation of an offer to buy financial products.



#### No Representation

The Issuer, the Lead Manager and any third party appointed by them make no representation or warranty relating to any information herein which is derived from independent sources.

#### No Advice

This Termsheet should not be construed as investment, financial, strategic, legal, regulatory, accounting or tax advice. It does not take into account the particular investment objectives, financial situation or needs of individual investors. Certain transactions, including those involving futures, options and high yield securities, give rise to substantial risk and are not suitable for all investors. Accordingly investors should consider whether the Products described herein are suitable for their particular circumstances and should consult their own accounting, tax, investment and legal advisors before investing. Marex Financial is not acting as an advisor or fiduciary. Marex Financial does not accept any responsibility to update any opinions or other information contained in this Termsheet.

#### No Bank Deposits

The Products are not bank deposits insured or guaranteed by the UK Financial Services Compensation Scheme or any other governmental agency or deposit protection fund run by public, private or community banks.

## DISCLAIMER

This document has been prepared by Marex Financial Products, a division of Marex Financial, for information purposes only. It is not intended as an offer or solicitation of the purchase or sale of any securities, funds, structured products or any other structured investment products ("Structured Investment Products"). Purchasing Structured Investment Products involve derivatives and a higher degree of risk factors that may not be suitable for all investors. Such risks include risk of adverse or unanticipated market developments, issuer credit quality risk, risk of counterparty or issuer default, risk of lack of uniform standard pricing, risk of adverse events involving any underlying reference obligations, entity or other measure, risk of high volatility, and risk of illiquidity/ little to no secondary market. In certain transactions, investors may lose their entire investment, i.e., incur an unlimited loss.

This document may only be distributed in countries where its distribution is legally permitted and may not be distributed in the US or to US persons. This document may not be distributed by Marex Financial Products or any distributor publicly and is only suitable for Qualified Investors (within the meaning of MIFID II) or equivalent investors.

This document was approved by Marex Financial. Marex Financial is incorporated under the laws of England and Wales (company no. 5613061, LEI no. 5493003EETVWYSIJ5A20 and VAT registration no. GB 872 8106 13) and is authorised and regulated by the Financial Conduct Authority (FCA registration number 442767). Marex Financial's registered address is at 155 Bishopsgate, London, EC2M 3TQ.

#### FTSE MIB Index

These Certificates are not in any way sponsored, endorsed, sold or promoted by FTSE International Limited ("FTSE") or by the London Stock Exchange Limited (the "Exchange") or by The Financial Times Limited ("FT") and neither FTSE nor Exchange or FT makes any warranty or representation whatsoever, expressly or impliedly, either as to the results to be obtained from the use of the FTSE MIB Index (the "Index") and/or the figure at which the said Index stands at any particular time on any particular day or otherwise. The Index is compiled and calculated solely by FTSE. However, neither FTSE nor Exchange or FT shall be liable (whether in negligence or otherwise) to any person for any error in the Index and neither FTSE nor Exchange nor FT shall be under any obligation to advise any person of any error therein.